Mattson Financial Services LLC Sells 3,781 Shares of Becton, Dickinson and Company $BDX

Key Points

• Mattson Financial Services LLC significantly reduced its holdings in Becton, Dickinson and Company by 88.1%, selling 3,781 shares and bringing their total to 509 shares, valued at approximately $117,000.
• Becton, Dickinson and Company reported earnings of $3.68 per share for the latest quarter, exceeding analysts' expectations and showing a 10.4% year-over-year revenue growth.
• The company declared a quarterly dividend of $1.04 per share, representing an annualized dividend yield of 2.2% and a payout ratio of 74.82%.

Mattson Financial Services LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 88.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 509 shares of the medical instruments supplier's stock after selling 3,781 shares during the period. Mattson Financial Services LLC's holdings in Becton, Dickinson and Company were worth $117,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. WBI Investments LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $872,000. IFM Investors Pty Ltd raised its stake in shares of Becton, Dickinson and Company by 1.0% during the 1st quarter. IFM Investors Pty Ltd now owns 53,623 shares of the medical instruments supplier's stock worth $12,283,000 after purchasing an additional 537 shares during the period. Integrity Alliance LLC. bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $269,000. Ransom Advisory Ltd bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $98,000. Finally, Glenview Trust co raised its stake in shares of Becton, Dickinson and Company by 18.9% during the 1st quarter. Glenview Trust co now owns 84,277 shares of the medical instruments supplier's stock worth $19,304,000 after purchasing an additional 13,404 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock valued at $551,536 in the last three months. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Up 1.1%

BDX stock opened at $190.52 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $54.61 billion, a PE ratio of 34.27, a PEG ratio of 1.41 and a beta of 0.27. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock has a 50-day simple moving average of $186.24 and a two-hundred day simple moving average of $192.03.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of research reports. Citigroup cut Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their price objective for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Barclays lowered their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Piper Sandler restated a "neutral" rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.